Actonel, Risedronate News

Dr Martin Scurr has been treating patients for more than 30 years and is one of the country's leading GPs.

Main Category: Bones / Orthopaedics Also Included In: Women's Health / Gynecology Article Date: 04 Sep 2009 New research has revealed a need for GPs to assess their patients' history more closely when prescribing for post-menopausal osteoporosis to reduce the risk of upper gastrointestinal side effects that could lead to treatment discontinuation.1 ...

If you're undergoing osteoporosis treatment, you're taking a step in the right direction for your bone health.

P&G Focuses on Winning in Consumer Health Care CINCINNATI and ARDEE, Ireland, Aug.

P&G Focuses on Winning in Consumer Health Care CINCINNATI and ARDEE, Ireland, Aug.

Here's an overview of the top prescription drug treatments in the United States for treating or preventing the bone-thinning disease osteoporosis: Alendronate Fosamax Merck & Co.

Ajinomoto Co., Inc. 15-1, Kyobashi 1-chome, Chuo-ku Tokyo 104-8315 JAPAN Tel: +81 5250-8111 Fax: +81 5250-8378 Comunicados de prensa 2009-07-31 Ajinomoto to Expand Osteoporosis Treatment Risedronate Business in Japan by Obtaining Related Assets Including Patents and Trademarks from P&G July 31, 2009 - Tokyo - Ajinomoto Co., Inc.

The Procter & Gamble Co. has sold Japanese market rights for its osteoporosis treatment to Ajinomoto Co.

Aclasta Approved In EU To Treat Steroid Induced Osteoporosis In Men And Post-menopausal Women Main Category: Bones / Orthopaedics Also Included In: Arthritis / Rheumatology Regulatory Affairs / Drug Approvals Aclasta [1] has been approved in the European Union to treat men and post-menopausal women with osteoporosis caused by the long-term use of ...

The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Steroids, widely used to treat inflammatory conditions, can cause bone loss and increase risk of fractures in up to 50% of patients on long-term therapy[1] * European approval based on data ...

We conducted the present study to investigate the therapeutic effects of a combination treatment of alfacalcidol and risedronate on the bone mechanical properties of bone and calcium metabolism using an ovariectomized rat model of osteoporosis.

The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France Clinical Therapeutics , Vol.

This places a significant burden in terms of morbidity, mortality and costs that are likely to increase with an ageing population.

TORONTO, JUNE 1 /CNW/ - Health Canada has approved Actonel 150 mg, Canada's first and only once-a-month dosing option in the treatment of postmenopausal osteoporosis.

Procter & Gamble sued Teva for infringing 5,583,122 after Teva let P&G know it was planning on marketing a generic version of P&G's osteoporosis drug ActonelA .

Teva, represented by Kenyon & Kenyon, lost its appeal from a decision of Judge Farnan in Procter & Gamble v. Teva over patents relating to the compound risedronate, the active ingredient of P&Ga s osteoporosis drug ActonelA .

CINCINNATI The U.S. Court of Appeals for the Federal Circuit ruled in favor of Procter & Gamble in the patent infringement lawsuit filed by P&G against Teva Pharmaceuticals over an osteoporosis therapy.